Dyadic International (DYAI) EBITDA Margin Growth (3y) (2021 - 2026)
Dyadic International (DYAI) EBITDA Margin Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -537.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1,934.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7,261.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,003.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -11,254.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30,461.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -2,649.00 |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 3,838.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,838.00 |
| Dec 31, 2025 | 39,665.00 |
| Sep 30, 2025 | 4,653.00 |
| Jun 30, 2025 | 32,496.00 |
| Mar 31, 2025 | -8,552.00 |
| Dec 31, 2024 | 115,846.00 |
| Sep 30, 2024 | 46,935.00 |
| Jun 30, 2024 | -11,664.00 |
| Mar 31, 2024 | 8,584.00 |
| Dec 31, 2023 | 34,000.00 |
| Sep 30, 2023 | 18,555.00 |
| Jun 30, 2023 | 26,010.00 |
| Mar 31, 2023 | 54,581.00 |
| Dec 31, 2022 | -14,003.00 |
| Sep 30, 2022 | 21,573.00 |
| Jun 30, 2022 | 25,383.00 |
| Mar 31, 2022 | 18,322.00 |
| Dec 31, 2021 | -108,864.00 |
| Sep 30, 2021 | 19,764.00 |
| Jun 30, 2021 | 71,342.00 |